Advertisement

Indoleamine 2,3-Dioxygenase and Regulatory Function: Tryptophan Starvation and Beyond

  • Ciriana Orabona
  • Ursula GrohmannEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 677)

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an ancestral enzyme that, initially confined to the regulation of tryptophan availability in local tissue microenvironments, is now considered to play a wider role that extends to homeostasis and plasticity of the immune system. Thus, IDO biology has many implications for many aspects of immunopathology, including viral infections, neoplasia, autoimmunity, and chronic inflammation. Its immunoregulatory effects are mainly mediated by dendritic cells (DCs) and involve not only tryptophan deprivation but also production of kynurenines that act on IDO DCs – thus rendering an otherwise stimulatory DC capable of regulatory effects – as well as on T cells. As a result, IDO+ DCs mediate multiple effects on T lymphocytes, including inhibition of proliferation, apoptosis, and differentiation toward a regulatory phenotype.

Key words

IDO Tryptophan catabolism Amino acid starvation Kynurenines Dendritic cells Regulatory T cells 

Notes

Acknowledgments

The Authors would like to thank Gianluca Andrielli for digital art.

References

  1. 1.
    Yamamoto, S., and Hayaishi, O. (1967) Tryptophan pyrrolase of rabbit intestine. d- and l-tryptophan-cleaving enzyme or enzymes. J. Biol. Chem. 242, 5260–5266.PubMedGoogle Scholar
  2. 2.
    Taylor, M. W., and Feng, G. S. (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5, 2516–2522.PubMedGoogle Scholar
  3. 3.
    Munn, D. H., Zhou, M., Attwood, J. T., et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191–1193.PubMedCrossRefGoogle Scholar
  4. 4.
    Sugimoto, H., Oda, S., Otsuki, T., et al. (2006) Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 103, 2611–2616.PubMedCrossRefGoogle Scholar
  5. 5.
    Mellor, A. L., and Munn, D. H. (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762–774.PubMedCrossRefGoogle Scholar
  6. 6.
    Macchiarulo, A., Nuti, R., Bellocchi, D., et al. (2007) Molecular docking and spatial coarse graining simulations as tools to investigate substrate recognition, enhancer binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO). Biochim. Biophys. Acta 1774, 1058–1068.PubMedCrossRefGoogle Scholar
  7. 7.
    Romani, L., Fallarino, F., De Luca, A., et al. (2008) Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451, 211–215.PubMedCrossRefGoogle Scholar
  8. 8.
    Alegre, E., Lopez, A. S., and Gonzalez, A. (2005) Tryptophan metabolites interfere with the Ehrlich reaction used for the measurement of kynurenine. Anal. Biochem. 339, 188–189.PubMedCrossRefGoogle Scholar
  9. 9.
    Belladonna, M. L., Volpi, C., Bianchi, R., et al. (2008) Cutting edge: autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 181, 5194–5198.PubMedGoogle Scholar
  10. 10.
    Belladonna, M. L., Orabona, C., Grohmann, U., and Puccetti, P. (2009) TGF-β and kynurenines as the key to infectious tolerance. Trends Mol. Med. 15, 41–49.PubMedCrossRefGoogle Scholar
  11. 11.
    Ueno, A., Cho, S., Cheng, L., et al. (2007) Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 56, 1686–1693.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhu, W. H., Lu, C. Z., Huang, Y. M., et al. (2007) A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells. Mult. Scler. 13, 33–40.PubMedCrossRefGoogle Scholar
  13. 13.
    von Bergwelt-Baildon, M. S., Popov, A., Saric, T., et al. (2006) CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108, 228–237.CrossRefGoogle Scholar
  14. 14.
    Fallarino, F., and Puccetti, P. (2006) Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. Eur. J. Immunol. 36, 8–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Grohmann, U., Orabona, C., Fallarino, F., et al. (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3, 1097–1101.PubMedCrossRefGoogle Scholar
  16. 16.
    Fallarino, F., Grohmann, U., Hwang, K. W., et al. (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206–1212.PubMedCrossRefGoogle Scholar
  17. 17.
    Orabona, C., Grohmann, U., Belladonna, M. L., et al. (2004) CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 5, 1134–1142.PubMedCrossRefGoogle Scholar
  18. 18.
    Orabona, C., Belladonna, M. L., Vacca, C., et al. (2005) Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J. Immunol. 174, 6582–6586.PubMedGoogle Scholar
  19. 19.
    Grohmann, U., Volpi, C., Fallarino, F., et al. (2007) Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat. Med. 13, 579–586.PubMedCrossRefGoogle Scholar
  20. 20.
    Muller, A. J., DuHadaway, J. B., Donover, P. S., et al. (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312–319.PubMedCrossRefGoogle Scholar
  21. 21.
    Orabona, C., Tomasello, E., Fallarino, F., et al. (2005) Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur. J. Immunol. 35, 3111–3118.PubMedCrossRefGoogle Scholar
  22. 22.
    Orabona, C., Puccetti, P., Vacca, C., et al. (2006) Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 107, 2846–2854.PubMedCrossRefGoogle Scholar
  23. 23.
    Orabona, C., Pallotta, M. T., Volpi, C., et al. (2008) SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. U.S.A. 105, 20828–20833.PubMedCrossRefGoogle Scholar
  24. 24.
    Ball, H. J., Yuasa, H. J., Austin, C. J., et al. (2009) Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 41, 467–471.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang, Y., Kang, S. A., Mukherjee, T., et al. (2007) Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis. Biochemistry 46, 145–155.PubMedCrossRefGoogle Scholar
  26. 26.
    Löb, S., Königsrainer, A., Schafer, R., et al. (2008) Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111, 2152–2154.PubMedCrossRefGoogle Scholar
  27. 27.
    Metz, R., Duhadaway, J. B., Kamasani, U., et al. (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan. Cancer Res. 67, 7082–7087.PubMedCrossRefGoogle Scholar
  28. 28.
    Grohmann, U., Fallarino, F., Bianchi, R., et al. (2003) A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med. 198, 153–160.PubMedCrossRefGoogle Scholar
  29. 29.
    Platten, M., Ho, P. P., Youssef, S., et al. (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310, 850–855.PubMedCrossRefGoogle Scholar
  30. 30.
    Gurtner, G. J., Newberry, R. D., Schloemann, S. R., et al. (2003) Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125, 1762–1773.PubMedCrossRefGoogle Scholar
  31. 31.
    Seo, S. K., Choi, J. H., Kim, Y. H., et al. (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10, 1088–1094.PubMedCrossRefGoogle Scholar
  32. 32.
    Popov, A., Abdullah, Z., Wickenhauser, C., et al. (2006) Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J. Clin. Invest. 116, 3160–3170.PubMedCrossRefGoogle Scholar
  33. 33.
    Hayashi, T., Beck, L., Rossetto, C., et al. (2004) Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114, 270–279.PubMedGoogle Scholar
  34. 34.
    Uyttenhove, C., Pilotte, L., Theate, I., et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274.PubMedCrossRefGoogle Scholar
  35. 35.
    Munn, D. H., Sharma, M. D., Hou, D., et al. (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280–290.PubMedGoogle Scholar
  36. 36.
    Curti, A., Trabanelli, S., Salvestrini, V., et al. (2009) The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 113, 2394–2401.PubMedCrossRefGoogle Scholar
  37. 37.
    Boasso, A., Herbeuval, J. P., Hardy, A. W., et al. (2007) HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109, 3351–3359.PubMedCrossRefGoogle Scholar
  38. 38.
    Prlic, M., and Bevan, M. J. (2009) Immunology: a metabolic switch to memory. Nature 460, 41–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Blander, J. M., and Amsen, D. (2009) Immunology. Amino acid addiction. Science 324, 1282–1283.PubMedCrossRefGoogle Scholar
  40. 40.
    Sharma, M. D., Hou, D. Y., Liu, Y., et al. (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113, 6102–6111.PubMedCrossRefGoogle Scholar
  41. 41.
    Munn, D. H., Sharma, M. D., Baban, B., et al. (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633–642.PubMedCrossRefGoogle Scholar
  42. 42.
    Cobbold, S. P., Adams, E., Farquhar, C. A., et al. (2009) Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl. Acad. Sci. U.S.A. 106, 12055–12060.PubMedCrossRefGoogle Scholar
  43. 43.
    Grohmann, U., Fallarino, F., and Puccetti, P. (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242–248.PubMedCrossRefGoogle Scholar
  44. 44.
    Hayashi, T., Mo, J. H., Gong, X., et al. (2007) 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc. Natl. Acad. Sci. U.S.A. 104, 18619–18624.PubMedCrossRefGoogle Scholar
  45. 45.
    Belladonna, M. L., Grohmann, U., Guidetti, P., et al. (2006) Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 177, 130–137.PubMedGoogle Scholar
  46. 46.
    Fallarino, F., Grohmann, U., You, S., et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752–6761.PubMedGoogle Scholar
  47. 47.
    Puccetti, P., and Grohmann, U. (2007) IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation. Nat. Rev. Immunol. 7, 817–823.PubMedCrossRefGoogle Scholar
  48. 48.
    Löb, S., Königsrainer, A., Rammensee, H. G., et al. (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9, 445–452.PubMedCrossRefGoogle Scholar
  49. 49.
    Yen, M. C., Lin, C. C., Chen, Y. L., et al. (2009) A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase. Clin. Cancer Res. 15, 641–649.PubMedCrossRefGoogle Scholar
  50. 50.
    Ménard, C., Ghiringhelli, F., Roux, S., et al. (2008) Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin. Cancer Res. 14, 5242–5249.PubMedCrossRefGoogle Scholar
  51. 51.
    Hryniewicz, A., Boasso, A., Edghill-Smith, Y., et al. (2006) CTLA-4 blockade decreases TGF-β, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108, 3834–3842.PubMedCrossRefGoogle Scholar
  52. 52.
    Fallarino, F., Bianchi, R., Orabona, C., et al. (2004) CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J. Exp. Med. 200, 1051–1062.PubMedCrossRefGoogle Scholar
  53. 53.
    Fallarino, F., Volpi, C., Zelante, T., et al. (2009) IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 183, 6303–6312.PubMedCrossRefGoogle Scholar
  54. 54.
    Muchamuel, T., Basler, M., Aujay, M. A.,et al. (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 15, 781–787.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2010

Authors and Affiliations

  1. 1.Department of Experimental Medicine and Biochemical SciencesUniversity of PerugiaPerugiaItaly

Personalised recommendations